...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS care. >Impact of maternal HAART on the prevention of mother-to-child transmission of HIV: results of an 18-month follow-up study in Ouagadougou, Burkina Faso.
【24h】

Impact of maternal HAART on the prevention of mother-to-child transmission of HIV: results of an 18-month follow-up study in Ouagadougou, Burkina Faso.

机译：孕妇HAART对预防HIV母婴传播的影响：在布基纳法索瓦加杜古进行的为期18个月的随访研究结果。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Mother-to-child transmission remains the main cause of global pediatric HIV infections, especially in sub-Saharan Africa. Many interventions based on single-dose antiretroviral therapy have been implemented to reduce the mother-to-child transmission of HIV. In resource-limited settings, highly active antiretroviral therapy (HAART) has only been recommended for HIV-infected pregnant women requiring treatment for their own health. Here, we assessed the efficacy over 18 months of maternal HAART versus peripartum short-course antiretroviral therapy (SCART) regimens for the prevention of mother-to-child transmission (PMTCT) of HIV. We conducted a retrospective cohort study of patients from two medical centers in Ouagadougou, Burkina Faso. The PMTCT files and registers from 1 January 2003 to 31 December 2006 were obtained from routine data collected at these sites. The main assessment criterion was the rate of HIV-1 positivity in children born to HIV-positive mothers as measured with HIV-1 rapid tests at 18 months. A total of 586 pregnant HIV-1-infected women in PMTCT programs were selected. Among these women, 260 were undergoing HAART and 326 received single-dose nevirapine (91.3%) or single-dose zidovudine (8.7%) at delivery. HIV-1 serological tests were performed on 454 children at 18 months old. The rate of HIV-1 vertical transmission was 0% (0/195) in the HAART group and 4.6% (12/259) in the single-dose monotherapy group (P<0.01). Eight infants in the HAART cohort and 30 in the SCART cohort were breastfed; three in the SCART group were HIV-positive. A total of 62 children died, 19 in the HAART group and 43 in the single-dose monotherapy group. Our study confirms that HAART for mothers effectively reduces the risk of infant HIV infection while preserving the breastfeeding option for mothers.
机译：母婴传播仍然是全球儿科艾滋病毒感染的主要原因，尤其是在撒哈拉以南非洲。已经实施了许多基于单剂量抗逆转录病毒疗法的干预措施，以减少艾滋病毒的母婴传播。在资源有限的情况下，仅对需要自身健康治疗的HIV感染孕妇推荐高活性抗逆转录病毒疗法（HAART）。在这里，我们评估了孕妇HAART相对于围产期短程抗逆转录病毒疗法（SCART）方案在18个月内预防HIV母婴传播（PMTCT）的疗效。我们对布基纳法索瓦加杜古两个医疗中心的患者进行了回顾性队列研究。 2003年1月1日至2006年12月31日的PMTCT文件和寄存器是从这些站点收集的常规数据中获得的。主要评估标准是在18个月内通过HIV-1快速测试测得的HIV阳性母亲所生孩子的HIV-1阳性率。在PMTCT计划中，总共选择了586名怀孕的HIV-1感染妇女。在这些妇女中，有260名正在接受HAART治疗，其中326名在分娩时接受了单剂量奈韦拉平（91.3％）或单剂量齐多夫定（8.7％）。对454名18个月大的儿童进行了HIV-1血清学检测。 HAART组的HIV-1垂直传播率为0％（0/195），单剂量单药治疗组为4.6％（12/259）（P <0.01）。 HAART队列中有8例婴儿，SCART队列中有30例进行了母乳喂养。 SCART组中有3名HIV阳性。共有62名儿童死亡，HAART组中有19名儿童死亡，单剂量单药治疗组中有43名儿童死亡。我们的研究证实，针对母亲的HAART可有效降低婴儿HIV感染的风险，同时保留针对母亲的母乳喂养方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号